{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:02:38Z","timestamp":1792785758546,"version":"4.5.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Vice-Chancellor for Research of the Mashhad University of Medical Science","id":[{"id":"https:\/\/ror.org\/04sfka033","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Helicobacter pylori infection is a global health concern associated with gastritis, peptic ulcer disease, and gastric cancer. With increasing antibiotic resistance, egg yolk immunoglobulin (IgY) has emerged as a promising candidate owing to its stability and pathogen-neutralizing effects. This clinical trial evaluated the efficacy of IgY-enriched egg yolk powder (anti-H. pylori IgY) in eliminating the bacterium and improving clinical symptoms as an adjunctive.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this randomized, double-blind trial, 60 patients with confirmed H. pylori infection received a 14-day standard therapy regimen (omeprazole, amoxicillin, clarithromycin) supplemented with IgY-enriched egg yolk powder (intervention) or plain egg yolk powder (control). The primary outcome was bacterial eradication, assessed by the 14C-urea breath test performed 4\u00a0weeks after completion of therapy (i.e. 6\u00a0weeks from baseline). Secondary outcomes included symptom improvement (abdominal pain, nausea, bloating, and anorexia) measured using the Gastrointestinal Symptom Rating Scale, via telephone interviews conducted three times weekly for 3\u00a0weeks. Data were analyzed using analysis of variance and t-tests (SPSS v24).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Baseline demographic characteristics were homogeneous. The median urea breath test value in the intervention group decreased from 77 to 11, whereas that of the control group remained unchanged (median\u00a0=\u00a055). Bacterial eradication was achieved in 33.3% of IgY recipients versus 13.3% of controls (difference, 20%; P\u00a0=\u00a0.241). IgY was well tolerated, with no treatment-related adverse events observed in the intervention group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Clinical symptoms showed trends toward faster improvement, but these did not reach statistical significance. IgY may be a promising safe adjunct for the treatment of H. pylori infection.<\/jats:p>\n                    <jats:p>Statement of Significance This study provides the current clinical perspective for immunoglobulin (IgY)-based therapy as an adjunct to standard therapy for Helicobacter pylori. Our findings suggest that IgY-enriched egg yolk powder can accelerate relief of symptoms without adverse effects. Although not sufficient to eradicate the bacteria, the reduction in urea breath test (mean 77 to 11) and the absence of adverse effects support IgY as a promising adjunct therapy and offers insights to guide future research on optimizing IgY formulations and developing safe and effective alternatives for H. pylori infection management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/abt\/tbag025","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T11:48:40Z","timestamp":1780055320000},"page":"471-479","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of IgY on\n                    <i>Helicobacter pylori<\/i>\n                    eradication and improvement of clinical symptoms: a randomized double-blind clinical trial"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6098-7471","authenticated-orcid":false,"given":"Zahra","family":"Esmaeili","sequence":"first","affiliation":[{"name":"Department of Microbiology and Virology, School of Medicine, Mashhad University of Medical Sciences , Mashhad , 9177948564,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Kamal Shahsavar","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Virology, School of Medicine, Mashhad University of Medical Sciences , Mashhad , 9177948564,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Khosravi","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Virology, School of Medicine, Mashhad University of Medical Sciences , Mashhad , 9177948564,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Ariannejad","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Ferdowsi University of Mashhad , Mashhad , 9177948974,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammadreza","family":"Nassiri","sequence":"additional","affiliation":[{"name":"Department of Agriculture, Ferdowsi University of Mashhad , Mashhad , 9177948978,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Beheshti Namdar","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Faculty of Medicine, Mashhad University of Medical Sciences , Mashhad , 91778 99191,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitra","family":"Ahadi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Faculty of Medicine, Mashhad University of Medical Sciences , Mashhad , 91778 99191,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Sadeghi","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Faculty of Medicine, Mashhad University of Medical Sciences , Mashhad , 9177948564,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahid Reza","family":"Dabbagh","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Faculty of Medicine, Mashhad University of Medical Sciences , Mashhad , 9177948564,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faezeh","family":"Sabet Birjandi","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Virology, School of Medicine, Mashhad University of Medical Sciences , Mashhad , 9177948564,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid","family":"Khadem Rezaiyan","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Faculty of Medicine, Mashhad University of Medical Sciences , Mashhad , 913791-3316,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8538-1425","authenticated-orcid":false,"given":"Kiarash","family":"Ghazvini","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Virology, School of Medicine, Mashhad University of Medical Sciences , Mashhad , 9177948564,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"2026100105270784800_ref1","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S1473-3099(24)00003-3","article-title":"Safety, pharmacokinetics, and efficacy of rifasutenizol, a novel dual-targeted antibacterial agent in healthy participants and patients in China with Helicobacter pylori infection: four randomised clinical trials","volume":"24","author":"Li","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2026100105270784800_ref2","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1136\/gutjnl-2022-327745","article-title":"Management of Helicobacter pylori infection: the Maastricht VI\/Florence consensus report","volume":"71","author":"Malfertheiner","year":"2022","journal-title":"Gut"},{"key":"2026100105270784800_ref3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S2468-1253(23)00281-9","article-title":"Primary antibiotic resistance of Helicobacter pylori in the Asia-Pacific region between 1990 and 2022: an updated systematic review and meta-analysis","volume":"9","author":"Hong","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026100105270784800_ref4","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/S2468-1253(23)00070-5","article-title":"Global prevalence of Helicobacter pylori infection between 1980 and 2022: a systematic review and meta-analysis","volume":"8","author":"Li","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026100105270784800_ref5","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1053\/j.gastro.2023.12.022","article-title":"Global prevalence of Helicobacter pylori infection and incidence of gastric cancer between 1980 and 2022","volume":"166","author":"Chen","year":"2024","journal-title":"Gastroenterology"},{"key":"2026100105270784800_ref6","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1136\/gutjnl-2015-309252","article-title":"Kyoto global consensus report on Helicobacter pylori gastritis","volume":"64","author":"Sugano","year":"2015","journal-title":"Gut"},{"key":"2026100105270784800_ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanmic.2024.100975","article-title":"Effects of amoxicillin dosage on cure rate, gut microbiota, and antibiotic resistome in vonoprazan and amoxicillin dual therapy for Helicobacter pylori: a multicentre, open-label, non-inferiority randomised controlled trial","volume":"6","author":"Hu","year":"2025","journal-title":"Lancet Microbe"},{"key":"2026100105270784800_ref8","doi-asserted-by":"publisher","first-page":"h4052","DOI":"10.1136\/bmj.h4052","article-title":"Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis","volume":"351","author":"Li","year":"2015","journal-title":"BMJ"},{"key":"2026100105270784800_ref9","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/S1473-3099(06)70627-2","article-title":"Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications","volume":"6","author":"Gerrits","year":"2006","journal-title":"Lancet Infect Dis"},{"key":"2026100105270784800_ref10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1136\/gutjnl-2012-302254","article-title":"Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption","volume":"62","author":"Megraud","year":"2013","journal-title":"Gut"},{"key":"2026100105270784800_ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-49415-3","article-title":"Effects of anti-H. pylori triple therapy and a probiotic complex on intestinal microbiota in duodenal ulcer","volume":"9","author":"Wu","year":"2019","journal-title":"Sci Rep"},{"key":"2026100105270784800_ref12","doi-asserted-by":"publisher","first-page":"13691","DOI":"10.1021\/acs.jafc.1c05398","article-title":"Potential therapeutic effects of egg yolk antibody (IgY) in Helicobacter pylori infections\u2014a review","volume":"69","author":"Zhang","year":"2021","journal-title":"J Agric Food Chem"},{"key":"2026100105270784800_ref13","doi-asserted-by":"publisher","first-page":"265","DOI":"10.4103\/ijmm.IJMM_18_19","article-title":"Antibiotic resistance in Helicobacter pylori: a mutational analysis from a tertiary care hospital in Kashmir, India","volume":"36","author":"Wani","year":"2018","journal-title":"Indian J Med Microbiol"},{"key":"2026100105270784800_ref14","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S2468-1253(17)30219-4","article-title":"Primary antibiotic resistance in Helicobacter pylori in the Asia-Pacific region: a systematic review and meta-analysis","volume":"2","author":"Kuo","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026100105270784800_ref15","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S0889-8553(05)70151-5","article-title":"The role of economic evaluation in the diagnosis and treatment of Helicobacter pylori infection","volume":"29","author":"Fendrick","year":"2000","journal-title":"Gastroenterol Clin North Am"},{"key":"2026100105270784800_ref16","doi-asserted-by":"publisher","first-page":"5116","DOI":"10.1128\/IAI.00547-09","article-title":"Antibody-mediated protection against infection with Helicobacter pylori in a suckling mouse model of passive immunity","volume":"77","author":"Gorrell","year":"2009","journal-title":"Infect Immun"},{"key":"2026100105270784800_ref17","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1128\/CDLI.9.5.1061-1066.2002","article-title":"Use of egg yolk-derived immunoglobulin as an alternative to antibiotic treatment for control of Helicobacter pylori infection","volume":"9","author":"Shin","year":"2002","journal-title":"Clin Diagn Lab Immunol"},{"key":"2026100105270784800_ref18","doi-asserted-by":"publisher","first-page":"95","DOI":"10.5455\/JMID.2024.v14.i3.2","article-title":"Chicken immunoglobulin (IgY) as an alternative treatment for bacterial infections, emphasizing advantages, disadvantages and mechanisms","volume":"14","author":"Esmaeili","year":"2024","journal-title":"J Microbiol Infect Dis"},{"key":"2026100105270784800_ref19","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/abt\/tbaf007","article-title":"A systematic review of the avian antibody (IgY) therapeutic effects on human bacterial infections over the decade","volume":"8","author":"Esmaeili","year":"2025","journal-title":"Antib Ther"},{"key":"2026100105270784800_ref20","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12937-015-0067-3","article-title":"IgY antibodies in human nutrition for disease prevention","volume":"14","author":"M\u00fcller","year":"2015","journal-title":"Nutr J"},{"key":"2026100105270784800_ref21","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.4161\/hv.23383","article-title":"Oral passive IgY-based immunotherapeutics: a novel solution for prevention and treatment of alimentary tract diseases","volume":"9","author":"Rahman","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"2026100105270784800_ref22","doi-asserted-by":"publisher","first-page":"746831","DOI":"10.3389\/fimmu.2021.746831","article-title":"Ex vivo evaluation of egg yolk IgY degradation in chicken gastrointestinal tract","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"2026100105270784800_ref23","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.3168\/jds.S0022-0302(04)73549-3","article-title":"Suppressive effect of functional drinking yogurt containing specific egg yolk immunoglobulin on Helicobacter pylori in humans","volume":"87","author":"Horie","year":"2004","journal-title":"J Dairy Sci"},{"key":"2026100105270784800_ref24","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1186\/s12879-024-09498-4","article-title":"Real-world evidence of a novel tetravalent immunoglobulin Y effectiveness and safety in patients with the refractory Helicobacter pylori infection","volume":"24","author":"Hao","year":"2024","journal-title":"BMC Infect Dis"},{"key":"2026100105270784800_ref25","doi-asserted-by":"publisher","first-page":"e12843","DOI":"10.1111\/hel.12843","article-title":"Dietary multivalent anti-Helicobacter pylori immunoglobulin Y significantly increase the H. pylori eradication and improve the clinical symptoms in patients","volume":"26","author":"Guo","year":"2021","journal-title":"Helicobacter"},{"key":"2026100105270784800_ref26","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2023.1150129","article-title":"Egg yolk antibody combined with bismuth-based quadruple therapy in Helicobacter pylori infection rescue treatment: a single-center, randomized, controlled study","volume":"14","author":"Cheng","year":"2023","journal-title":"Front Microbiol"},{"key":"2026100105270784800_ref27","doi-asserted-by":"publisher","DOI":"10.18502\/ijm.v17i3.18823","article-title":"Evaluation of the prevention, treatment and synergistic activity between Helicobacter pylori IgY antibodies and pantaprazole on AGS cell line and C57BL\/6 Mice","volume":"17","author":"Sara, Kamal","year":"2025","journal-title":"Iran J Microbiol"},{"key":"2026100105270784800_ref28","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3103\/S0891416825700089","article-title":"Production of polyclonal whole-cell anti-IgY against Helicobacter pylori and determination of its stability in environmental conditions and interaction with Salmonella and E. coli","volume":"40","author":"Shahsavar","year":"2025","journal-title":"Mol Genet Microbiol Virol"},{"key":"2026100105270784800_ref29","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1023\/A:1008841022998","article-title":"Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease","volume":"7","author":"Revicki DA","year":"1998","journal-title":"Qual Life Res"},{"key":"2026100105270784800_ref30","doi-asserted-by":"publisher","first-page":"147","DOI":"10.34172\/mejdd.2024.389","article-title":"An update on eradication of Helicobacter pylori in Iran: a review","volume":"16","author":"Ebrahimi","year":"2024","journal-title":"Middle East J Dig Dis"},{"key":"2026100105270784800_ref31","first-page":"358","article-title":"Comparison of the success effect of three different treatment regimens on Helicobacter pylori eradication: randomized clinical trial","volume":"83","author":"Zamanifard","year":"2025","journal-title":"Tehran Univ Med J"}],"container-title":["Antibody Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/abt\/advance-article-pdf\/doi\/10.1093\/abt\/tbag025\/68442918\/tbag025.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/abt\/article-pdf\/9\/4\/471\/68442918\/tbag025.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/abt\/article-pdf\/9\/4\/471\/68442918\/tbag025.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:27:12Z","timestamp":1790846832000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/abt\/article\/9\/4\/471\/8699372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/abt\/tbag025","relation":{},"ISSN":["2516-4236"],"issn-type":[{"value":"2516-4236","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,6,1]]}}}